Tower Research Capital (TRC)’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Tower Research Capital (TRC)’s Portfolio CANF Stock Details CANF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Hold	0	–	-$1K	–	4447
2016 Q1	–	Hold	0	–	–	–	3645
2015 Q4	–	Hold	0	–	–	–	4503
2015 Q3	–	Hold	0	–	–	–	4041
2015 Q2	–	Hold	0	–	–	–	3962
2015 Q1	–	Sell	-1	Closed	-$12K	–	3736
2014 Q4	$5K	Buy	+1	New	+$10K	﹤0.01%	2683
2014 Q1	–	Hold	0	–	-$7K	–	4470
2013 Q4	–	Hold	0	–	–	–	3277

Other funds holding CANF

TAM

Taylor Asset Management Toronto, Ontario, Canada $154M AUM 10.32% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.8M AUM 57.47% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Tower Research Capital (TRC)'s CANF Position: Q2 2016 in Review

Tower Research Capital (TRC) held its Can-Fite BioPharma American Depositary Shares (CANF) position steady in Q2 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4447.

Tower Research Capital (TRC) first reported a position in CANF in Q4 2014 and has held it in 1 quarter since. The position peaked at $5K in Q4 2014. 9 funds tracked by Wall St. Rank hold CANF as of Q2 2016.

Tower Research Capital (TRC) held 0 shares of Can-Fite BioPharma American Depositary Shares worth $0 as of Q2 2016.
Tower Research Capital (TRC) left its Can-Fite BioPharma American Depositary Shares share count unchanged in Q2 2016.
Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2016, its #4447 holding.
Tower Research Capital (TRC) first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2014 and has held it in 1 quarter since.
Tower Research Capital (TRC)'s Can-Fite BioPharma American Depositary Shares position peaked at $5K in Q4 2014.
9 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q2 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2016, filed 10 Aug 2016.